Frazier Life Sciences Management’s Allogene Therapeutics ALLO Stock Holding History

Frazier Life Sciences Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.7M	Buy	22,446,668 +18,650,000	+491%	+$41M	1.02%	21
2026 Q1	$9.26M	Sell	3,796,668 -72,082	-2%	-$144K	0.24%	35
2025 Q4	$5.3M	Hold	3,868,750	–	–	0.14%	37
2025 Q3	$4.8M	Hold	3,868,750	–	–	0.14%	46
2025 Q2	$4.37M	Hold	3,868,750	–	–	0.17%	45
2025 Q1	$5.65M	Buy	3,868,750 +1,001,000	+35%	+$1.89M	0.26%	39
2024 Q4	$6.11M	Hold	2,867,750	–	–	0.25%	45
2024 Q3	$8.03M	Hold	2,867,750	–	–	0.32%	41
2024 Q2	$6.68M	Hold	2,867,750	–	–	0.31%	43
2024 Q1	$12.8M	Buy	+2,867,750	New	+$12M	0.54%	39

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Frazier Life Sciences Management's ALLO Position: Q2 2026 in Review

Frazier Life Sciences Management increased its Allogene Therapeutics (ALLO) stake by 491% in Q2 2026, buying an estimated $41M and bringing the position to 22,446,668 shares worth $46.7M. The position accounts for 1.02% of the portfolio, ranked #21.

Frazier Life Sciences Management first reported a position in ALLO in Q1 2024 and has held it in 10 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Frazier Life Sciences Management held 22,446,668 shares of Allogene Therapeutics worth $46.7M as of Q2 2026.
Frazier Life Sciences Management bought 18,650,000 Allogene Therapeutics shares in Q2 2026, an estimated $41M.
Allogene Therapeutics made up 1.02% of Frazier Life Sciences Management's portfolio in Q2 2026, its #21 holding.
Frazier Life Sciences Management first reported a position in Allogene Therapeutics in Q1 2024 and has held it in 10 quarters since.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.